Praluent and Repatha recommended by NICE for cholesterol disorder

6 May 2016

UK government medicines cost-effectiveness body the National Institute for Health Care Excellence (NICE) has published new draft guidance recommending two new treatment options for suitable patients with conditions that put them at extremely high risk of heart attacks or strokes.

These drugs are Praluent (alirocumab), marketed by French pharma giant Sanofi (Euronext: SAN), and Repatha (evolocumab), the rights to which belong to US biotech Amgen (Nasdaq: AMGN).

They are recommended for adults with primary hypercholesterolaemia or mixed dyslipidaemia, to help reduce their risk of cardiovascular disease. The drugs are described as suitable for people with these conditions whose cholesterol levels are not controlled adequately using other drugs such as statins.They are also recommended for those who cannot tolerate statins due to their side effects or have another condition which means they cannot take them.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK